Abstract 5189
Background
Small cell lung cancer (SCLC) is a highly lethal disease. Recently, immunotherapy has demonstrated a benefit for a subgroup of patients beyond the second-line and in the first-line setting combined with chemotherapy. However, the majority of patients will not benefit and predictive biomarkers are urgently needed. High baseline neutrophil count (NC) and neutrophil-to-lymphocyte ratio (NLR) are unfavorable prognostic factors in SCLC and might also predict for lack of response to immunotherapy. There is data suggesting that activation of the HGF/MET pathway might contribute to the recruitment of immunosuppressor neutrophils in the tumor. Our aim was to evaluate the association between HGF serum levels (sHGF) and NC in SCLC and their impact on outcome.
Methods
Serum samples from SCLC patients were obtained before starting first-line treatment. We used the Quantikine Human HGF Immunoassay to quantify sHGF. All samples were run in duplicates. NC and NLR were obtained from blood test reports before treatment initiation. Statistical analysis was carried out using SPSS 22.0 and Prism 8.1.0. Correlation of variables was assessed by the Spearman’s correlation coefficient. Multivariate analysis was performed with the Cox regression method.
Results
Samples from 105 patients diagnosed with SCLC at our institution were included. 79.1% of the cases were male, 73.3% with extensive stage, and 31.4% had an ECOG score of ≥ 2. Median sHGF, NC and NLR were 1875.38pg/ml, 6440/µl and 5.1 respectively. Patients with baseline NLR > 4 or NC above median had worse median overall survival (mOS), with 7.9 vs 15.3 months (m) (p < 0.001) and 7.2 vs 15.3m (p < 0.001) respectively. sHGF above median values was also correlated with worse mOS (7.6 vs 12.8 m; p = 0.005). Baseline sHGF levels were positively correlated with NC (r = 0.34, p < 0.001). In the multivariate analysis for OS, sHGF and NC remained independently associated with poor outcome (HR 1.094; p = 0.001 and HR 1.18; p = 0.003 respectively).
Conclusions
Baseline HGF levels correlate with NC in SCLC, reinforcing the hypothesis of a plausible interplay between HGF/MET axis and the immune system. The role of these parameters as predictive biomarkers of response to immunotherapy in SCLC warrants further investigation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
E. Arriola: Speaker Bureau / Expert testimony: BMS; Speaker Bureau / Expert testimony: Roche; Speaker Bureau / Expert testimony: MSD; Speaker Bureau / Expert testimony: Pfizer; Speaker Bureau / Expert testimony: Lilly; Speaker Bureau / Expert testimony: AstraZeneca; Research grant / Funding (institution): BMS; Research grant / Funding (institution): Roche; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): PGDx; Travel / Accommodation / Expenses: BMS; Travel / Accommodation / Expenses: MSD; Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: Lilly. All authors have declared no conflicts of interest.
Resources from the same session
4526 - Long-term outcome of neoadjuvant tyrosine kinase inhibitors (TKI) in locally advanced dermatofibrosarcoma protuberans (DFSP)
Presenter: Jessica Beaziz
Session: Poster Display session 1
Resources:
Abstract
1214 - Neo-adjuvant (NA) Imatinib for gastrointestinal stromal tumours (GISTs): What is the optimal length of treatment?
Presenter: Tom Wilson
Session: Poster Display session 1
Resources:
Abstract
2690 - Gastrointestinal Stromal Tumours (GIST) in adolescents and young adults (AYA)
Presenter: Nikki Ijzerman
Session: Poster Display session 1
Resources:
Abstract
4558 - Radiomics improves response evaluation for desmoid tumors treated with chemotherapy
Presenter: Amandine Crombe
Session: Poster Display session 1
Resources:
Abstract
2751 - Radiomics of gastrointestinal stromal tumors; risk classification based on computed tomography images – a pilot study
Presenter: Milea Timbergen
Session: Poster Display session 1
Resources:
Abstract
2737 - Differentiating well-differentiated liposarcomas from lipomas using a radiomics approach
Presenter: Melissa Vos
Session: Poster Display session 1
Resources:
Abstract
1282 - The immune landscape of chondrosarcoma reveals an anti inflammatory environment
Presenter: Iseulys Richert
Session: Poster Display session 1
Resources:
Abstract
1572 - Impact of Immunotherapy and Targeted Therapy on Tumor Growth Rate in Sarcoma
Presenter: Esmail Al-ezzi
Session: Poster Display session 1
Resources:
Abstract
3414 - DNA methylation profiles of angiosarcoma subtypes.
Presenter: Marije Weidema
Session: Poster Display session 1
Resources:
Abstract
3411 - Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As and BTN3A1 in patients with metastatic gastrointestinal stromal tumors (mGISTs)
Presenter: Daniele Fanale
Session: Poster Display session 1
Resources:
Abstract